Oxycodonhydrochlorid 1 A Pharma (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Oxycodonhydrochlorid 1 A Pharma, is an opioid analgesic presented as a 1 mg oral tablet for oral use. It is prescribed for moderate to severe pain management in adult patients. GNH USA supplies Oxycodonhydrochlorid 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxycodonhydrochlorid 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxycodone Hydrochloride is used within the opioid analgesic pathway to treat pain of varying intensity. - Acute postoperative pain: provides rapid relief of pain following surgical procedures. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Chronic non‑cancer pain: used when other analgesics are insufficient for long‑term pain management. - Severe traumatic injury pain: reduces intense pain resulting from major injuries. - Palliative care pain: alleviates pain in end‑of‑life care settings.

Adverse reactions to oxycodone may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness or sedation: increased sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or imbalance. - Dry mouth: reduced salivary flow causing oral discomfort. - Pruritus: mild itching without rash.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Opioid use disorder: risk of dependence, tolerance, and addiction. - Seizures: rare occurrence of convulsive episodes. - Anaphylaxis: acute allergic reaction with airway compromise. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing oxycodone, clinicians should consider several safety measures. - Assess pain severity and treatment goals: ensure opioid therapy is appropriate for the patient’s condition. - Evaluate risk of respiratory depression: monitor breathing, especially after dose initiation or escalation. - Review patient history for substance use disorder: identify potential for misuse or dependence. - Adjust dose in renal or hepatic impairment: consider reduced clearance in organ dysfunction. - Avoid concomitant CNS depressants: limit use with benzodiazepines or alcohol. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Oxycodone may interact with a range of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined use with other strong opioids: increases risk of respiratory depression and profound sedation. - Concurrent benzodiazepines or barbiturates: synergistic CNS depression can be fatal. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): elevate oxy‑hydrochloride plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may reduce conversion to active metabolites, affecting analgesia. - Anticholinergic agents: can worsen constipation and urinary retention. - Diuretics: may enhance hypotensive effects, requiring blood pressure monitoring.